Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
ALK tyrosine kinase inhibitor

Nelkarmi (neladalkib)

An approved treatment for ALK-Positive Lung Cancer.

FDA Approved (2026)by Nuvalent, Inc., part of GSK since July 2026
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2026

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Neladalkib wherever you encounter it, plus the key facts at a glance.

Generic name
Neladalkib
Brand name
Nelkarmi
Development code
NVL-655
Drug class
ALK tyrosine kinase inhibitor
Manufacturer
Nuvalent, Inc., part of GSK since July 2026
How it's taken
Oral tablets, once a day

Nelkarmi (neladalkib) is a pill taken once a day for ALK-positive non-small cell lung cancer.

  • The FDA granted it accelerated approval on November 17, 2026 for adults whose cancer is locally advanced or has spread, after earlier ALK-targeted treatment[2][1]. It is for people whose only earlier ALK inhibitor for advanced or metastatic disease was alectinib (Alecensa). It is also for people who have taken 2 or more ALK inhibitors plus platinum chemotherapy for advanced or metastatic disease[1].
  • Alectinib taken only after surgery for early-stage cancer does not count toward the label's requirement[1].
  • Nuvalent developed it under the code NVL-655, and GSK completed its purchase of Nuvalent on July 15, 2026[3][4].
  • In the ALKOVE-1 trial, tumors shrank in 49% of people whose only earlier ALK inhibitor was alectinib.
  • Tumors shrank in 32% of people who had taken 2 or more ALK inhibitors and chemotherapy[1].
Follow Nelkarmi by email

We'll email you when Nelkarmi's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Neladalkib fits

Nelkarmi (neladalkib) is a once-daily ALK inhibitor pill for adults with advanced ALK-positive lung cancer. It is for cancer that has grown after alectinib given for advanced disease, or after 2 or more ALK inhibitors and platinum chemotherapy[1].

  • Alectinib (Alecensa), brigatinib (Alunbrig), lorlatinib (Lorbrena), crizotinib (Xalkori) and ceritinib (Zykadia) are FDA approved for metastatic ALK-positive lung cancer[9][11][10][12][13].
  • Ensartinib (Ensacove) is FDA approved for this cancer in people who have not yet taken an ALK inhibitor[14].
  • Nelkarmi's approval came from a single-arm trial, and no trial has compared it directly with lorlatinib or chemotherapy for cancer that grew after alectinib[1][6].
  • The Phase 3 ALKAZAR trial is comparing neladalkib with alectinib in people who have not taken an ALK inhibitor[7].
  • Anyone curious about neladalkib can ask their oncologist whether a biopsy or blood test for ALK resistance changes would help guide the next treatment.

How Neladalkib works

In ALK-positive lung cancer, a piece of the ALK gene joins another gene inside the tumor, most often one called EML4. LUNGevity explains that the fused protein keeps telling the cancer cells to grow[8]. ALK inhibitor pills block that signal. Over time, though, the cancer can change the ALK protein in ways that stop the drug from fitting.

One of these resistance changes is called G1202R[1]. Neladalkib blocks ALK, including forms with G1202R and with 2 resistance changes at once, in laboratory tests[1]. GSK says it was designed to cover a broad range of ALK resistance changes, to cross into the brain and to be highly selective for its target[3]. In the label's laboratory tests, neladalkib also blocked a related protein called ROS1 about as strongly as ALK, and blocked TRK proteins far less strongly[1].

Side effects and safety

What patients report

Nelkarmi has no boxed warning, and the label lists no contraindications[1]. The label's 5 warnings are liver problems, kidney problems, eye problems, a rise in the muscle enzyme CPK and harm to an unborn baby[1].

Liver: Across 700 people treated in ALKOVE-1, liver side effects occurred in 56%, and were grade 3 in 18% and grade 4 in 7%[1]. Grade 3 or 4 liver failure occurred in 0.4%, and grade 3 or 4 drug-induced liver injury in 0.3%[1]. The median time to a first rise in liver enzymes was 16 days[1]. Liver blood tests are checked before starting, every 2 weeks for the first 2 months, then monthly and as needed[1].

Kidneys: Creatinine, a kidney blood test, rose in 24% and acute kidney injury occurred in 1.1%[1]. Creatinine is checked before starting, every 2 weeks for the first month, then from time to time[1].

Eyes: Eye side effects occurred in 14%, including rare cases of retinal detachment and damage to the surface of the eye. The label says to see an eye care professional promptly for new or worse vision symptoms[1].

Muscle enzyme: CPK rose in 28%, and is checked before starting and every 2 weeks for the first 2 months[1].

Pregnancy: Nelkarmi can harm an unborn baby. The label calls for effective nonhormonal birth control during treatment and for 2 weeks after the last dose. This is because Nelkarmi's effect on hormonal birth control is unknown. The label also calls for male patients with partners who could become pregnant to use birth control for the same time[1]. Breastfeeding is not advised during treatment and for 2 weeks after[1].

Most common: In the 656 people with ALK-positive lung cancer, the most common side effects were liver problems (57%) and muscle and joint pain (33%). The other most common side effects were constipation (28%), a change in taste (25%), nerve tingling or numbness in the hands or feet (23%), tiredness (21%) and swelling (20%)[1]. Serious side effects occurred in 30%.

Fatal side effects occurred in 1.1% and included cardiac arrest, a blood clot in the lung, sudden death and pneumonia[1]. Of the 656, 5% stopped Nelkarmi for good because of side effects, most often liver problems[1].

Lab changes: Cholesterol rose in 45% and triglycerides in 25%. The label lists QT prolongation, a change in the heart's rhythm on an ECG, among less common side effects[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Neladalkib

The label dose is 150mg by mouth once a day, at the same time each day, with or without food[1]. Tablets come in 50mg and 150mg strengths and are swallowed whole, not split, chewed, crushed or dissolved[1]. A dose missed by more than 12 hours is skipped, and no extra dose is taken after vomiting[1].

For side effects, the doctor may pause Nelkarmi or lower the dose to 100mg and then 50mg once a day. Nelkarmi is stopped for good in people who cannot tolerate 50mg[1].

Before starting: Liver tests, creatinine and CPK are checked, and a pregnancy test is done for anyone who could become pregnant[1].

Other medicines: Neladalkib is broken down mainly by the enzyme CYP3A4[1]. The label says to avoid strong and moderate CYP3A inhibitors and inducers, since they can raise or lower neladalkib levels[1]. Taking lansoprazole, a stomach acid reducer, did not change neladalkib levels in a study[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Nelkarmi

The maker of Nelkarmi publishes no copay card, but its support program can check your insurance and explain any help that exists. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Nelkarmi (Neladalkib)
Some details not published
  • Insurance and case manager help

    Nuvalent Patient Support lists Nelkarmi 50mg and 150mg tablets. Its Nelkarmi page says the program is coming soon and gives (844) 688-5333, Monday to Friday 8 AM to 8 PM ET, to enroll or learn more.

    The official page does not say who qualifies. Ask the program. · source

Good to know: The FDA granted accelerated approval on November 17, 2026. Nuvalent, now part of GSK, has published no copay card amount, free-drug program, eligibility rules or list price for Nelkarmi. nelkarmi.com was not live and GSK's TogetherWithGSK site does not list Nelkarmi. Check again once the Nelkarmi support page goes live. Every non-small cell lung cancer charity fund checked on November 18, 2026 was closed.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for ALK-Positive Lung Cancer

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for ALK-Positive Lung Cancer →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

ALKOVE-1 (NCT05384626) is a single-arm, open-label Phase 1/2 trial in which everyone takes neladalkib, with no comparison group[1][6]. The approval rests on 222 adults with ALK-positive non-small cell lung cancer who had already taken ALK inhibitors, and response was judged by reviewers outside the study sites[1].

After alectinib alone: In 67 people whose only earlier ALK inhibitor was alectinib, tumors shrank in 49%, including 7% whose tumors disappeared on scans[1]. Among responders, 76% had responses lasting at least 6 months and 52% at least 12 months[1].

After 2 or more ALK inhibitors: Tumors shrank in 32% of 155 people who had taken 2 or more ALK inhibitors and platinum chemotherapy. Most of them had taken both lorlatinib and alectinib. The median response lasted 17.3 months[1]. Among responders, 69% had responses lasting at least 6 months and 51% at least 12 months[1].

Brain: The label also reports results in people with measurable brain metastases who had not had brain radiation in the 2 months before. Brain tumors shrank in 55% of 20 people after alectinib alone. They shrank in 26% of 53 people after 2 or more ALK inhibitors[1].

Resistance change G1202R: Response rates were 77% in 13 people with G1202R after alectinib alone and 71% in 35 people with G1202R after 2 or more ALK inhibitors[1].

ALKAZAR (NCT06765109) is a Phase 3 trial comparing neladalkib with alectinib in about 450 people with advanced ALK-positive lung cancer who have not taken an ALK inhibitor. It was recruiting at 22 open US sites when ClinicalTrials.gov was checked on November 18, 2026[7].

Development history

Nuvalent is a company based in Cambridge, Massachusetts. It designed neladalkib under the code NVL-655 and began ALKOVE-1 in June 2022[6]. Nuvalent said on May 27, 2026 that the FDA had accepted its New Drug Application with Priority Review and a target date of November 27, 2026[5]. GSK completed its purchase of Nuvalent on July 15, 2026[4].

The FDA had given neladalkib Breakthrough Therapy and Orphan Drug designations. It granted accelerated approval on November 17, 2026, 10 days before the target date[2][3]. Accelerated approval rests on how many tumors shrank and how long that lasted, and continued approval may depend on a confirmatory trial[1].

Ask anything about Neladalkib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore ALK-Positive Lung Cancer trials

Other ALK-Positive Lung Cancer treatments

Common questions about Neladalkib

▸What is Neladalkib (Nelkarmi)?

Nelkarmi (neladalkib) is a pill taken once a day for ALK-positive non-small cell lung cancer. The FDA granted it accelerated approval on November 17, 2026 for adults whose cancer is locally advanced or has spread, after earlier ALK-targeted treatment[2][1]. It is for people whose only earlier ALK inhibitor for advanced or metastatic disease was alectinib (Alecensa). It is also for people who have taken 2 or more ALK inhibitors plus platinum chemotherapy for advanced or metastatic disease[1]. Alectinib taken only after surgery for early-stage cancer does not count toward the label's requirement[1]. Nuvalent developed it under the code NVL-655, and GSK completed its purchase of Nuvalent on July 15, 2026[3][4]. In the ALKOVE-1 trial, tumors shrank in 49% of people whose only earlier ALK inhibitor was alectinib. Tumors shrank in 32% of people who had taken 2 or more ALK inhibitors and chemotherapy[1].

▸How does Neladalkib work?

In ALK-positive lung cancer, a piece of the ALK gene joins another gene inside the tumor, most often one called EML4. LUNGevity explains that the fused protein keeps telling the cancer cells to grow[8]. ALK inhibitor pills block that signal. Over time, though, the cancer can change the ALK protein in ways that stop the drug from fitting. One of these resistance changes is called G1202R[1]. Neladalkib blocks ALK, including forms with G1202R and with 2 resistance changes at once, in laboratory tests[1]. GSK says it was designed to cover a broad range of ALK resistance changes, to cross into the brain and to be highly selective for its target[3]. In the label's laboratory tests, neladalkib also blocked a related protein called ROS1 about as strongly as ALK, and blocked TRK proteins far less strongly[1].

▸What are the side effects of Neladalkib?

Nelkarmi has no boxed warning, and the label lists no contraindications[1]. The label's 5 warnings are liver problems, kidney problems, eye problems, a rise in the muscle enzyme CPK and harm to an unborn baby[1].

Liver: Across 700 people treated in ALKOVE-1, liver side effects occurred in 56%, and were grade 3 in 18% and grade 4 in 7%[1]. Grade 3 or 4 liver failure occurred in 0.4%, and grade 3 or 4 drug-induced liver injury in 0.3%[1]. The median time to a first rise in liver enzymes was 16 days[1]. Liver blood tests are checked before starting, every 2 weeks for the first 2 months, then monthly and as needed[1].

Kidneys: Creatinine, a kidney blood test, rose in 24% and acute kidney injury occurred in 1.1%[1]. Creatinine is checked before starting, every 2 weeks for the first month, then from time to time[1].

Eyes: Eye side effects occurred in 14%, including rare cases of retinal detachment and damage to the surface of the eye. The label says to see an eye care professional promptly for new or worse vision symptoms[1].

Muscle enzyme: CPK rose in 28%, and is checked before starting and every 2 weeks for the first 2 months[1].

Pregnancy: Nelkarmi can harm an unborn baby. The label calls for effective nonhormonal birth control during treatment and for 2 weeks after the last dose. This is because Nelkarmi's effect on hormonal birth control is unknown. The label also calls for male patients with partners who could become pregnant to use birth control for the same time[1]. Breastfeeding is not advised during treatment and for 2 weeks after[1].

Most common: In the 656 people with ALK-positive lung cancer, the most common side effects were liver problems (57%) and muscle and joint pain (33%). The other most common side effects were constipation (28%), a change in taste (25%), nerve tingling or numbness in the hands or feet (23%), tiredness (21%) and swelling (20%)[1]. Serious side effects occurred in 30%. Fatal side effects occurred in 1.1% and included cardiac arrest, a blood clot in the lung, sudden death and pneumonia[1]. Of the 656, 5% stopped Nelkarmi for good because of side effects, most often liver problems[1].

Lab changes: Cholesterol rose in 45% and triglycerides in 25%. The label lists QT prolongation, a change in the heart's rhythm on an ECG, among less common side effects[1].

▸How is Neladalkib taken?

The label dose is 150mg by mouth once a day, at the same time each day, with or without food[1]. Tablets come in 50mg and 150mg strengths and are swallowed whole, not split, chewed, crushed or dissolved[1]. A dose missed by more than 12 hours is skipped, and no extra dose is taken after vomiting[1].

For side effects, the doctor may pause Nelkarmi or lower the dose to 100mg and then 50mg once a day. Nelkarmi is stopped for good in people who cannot tolerate 50mg[1].

Before starting: Liver tests, creatinine and CPK are checked, and a pregnancy test is done for anyone who could become pregnant[1].

Other medicines: Neladalkib is broken down mainly by the enzyme CYP3A4[1]. The label says to avoid strong and moderate CYP3A inhibitors and inducers, since they can raise or lower neladalkib levels[1]. Taking lansoprazole, a stomach acid reducer, did not change neladalkib levels in a study[1].

▸Is Neladalkib FDA approved?

Yes, Neladalkib (Nelkarmi) is FDA approved (2026) for the treatment of ALK-Positive Lung Cancer.

▸Is neladalkib FDA approved?

Yes. The FDA granted accelerated approval to neladalkib as Nelkarmi on November 17, 2026.

Who it is for: Adults with locally advanced or metastatic ALK-positive non-small cell lung cancer whose only earlier ALK inhibitor for advanced or metastatic disease was alectinib. It is also for adults with this cancer who have taken 2 or more ALK inhibitors plus platinum chemotherapy for advanced or metastatic disease.

Dose: 150mg by mouth once a day, with or without food.

Accelerated approval: It rests on tumor response and how long responses lasted, and continued approval may depend on a confirmatory trial.

Safety: The label has no boxed warning.

More: ALK-positive lung cancer treatments compared

Source: Nelkarmi prescribing information, November 2026; FDA approval notice, November 17, 2026

▸What did the ALKOVE-1 trial of neladalkib show?

Tumors shrank in 49% of people whose only earlier ALK inhibitor was alectinib, and in 32% of people who had taken 2 or more ALK inhibitors and chemotherapy.

How long: About half of responders in each group had responses lasting a year or longer, and the median response after 2 or more ALK inhibitors lasted 17.3 months.

Brain: Brain metastases shrank in 55% of 20 people after alectinib alone and in 26% of 53 people after 2 or more ALK inhibitors.

G1202R: Response rates were 77% and 71% in people whose cancer carried this resistance change.

Design: Everyone took neladalkib, with no comparison group, which means the results cannot be lined up against another drug.

Source: Nelkarmi prescribing information, November 2026

▸What are the side effects of neladalkib?

Liver side effects were the most common, in 57% of people with ALK-positive lung cancer in ALKOVE-1.

Other common ones: Muscle and joint pain (33%), constipation (28%), a change in taste (25%), tingling or numbness in the hands or feet (23%), tiredness (21%) and swelling (20%).

Warnings: Liver problems, kidney problems, eye problems including rare retinal detachment, a rise in the muscle enzyme CPK, and harm to an unborn baby.

Monitoring: Liver tests and CPK every 2 weeks for the first 2 months, and creatinine every 2 weeks for the first month.

Stopping: Of the 656 people, 5% stopped Nelkarmi for good because of side effects, most often liver problems. Side effects were fatal in 1.1%.

Lab changes: Cholesterol rose in 45% and triglycerides in 25%.

Source: Nelkarmi prescribing information, November 2026

▸Can neladalkib be taken after lorlatinib?

The label covers people who have taken lorlatinib if they have had 2 or more ALK inhibitors plus platinum chemotherapy for advanced or metastatic disease.

In the trial: Among the 155 people in that group, 95% had taken lorlatinib and 84% had taken both lorlatinib and alectinib, and tumors shrank in 32%.

After alectinib only: The label also covers people whose only earlier ALK inhibitor for advanced or metastatic disease was alectinib, with no chemotherapy required first. Alectinib taken only after surgery does not count.

Other earlier drugs: The label's indication does not cover people whose single earlier ALK inhibitor was something other than alectinib.

Source: Nelkarmi prescribing information, November 2026

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf
  2. U.S. Food and Drug Administration · 2026-11-17. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk
  3. GSK plc · 2026-11-17. Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer. https://www.gsk.com/en-gb/media/press-releases/nelkarmi-neladalkib-approved-in-the-us-for-previously-treated-advanced-alk-positive-non-small-cell-lung-cancer/
  4. GSK plc · 2026-07-15. GSK completes acquisition of Nuvalent, Inc. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/
  5. Nuvalent, Inc. · 2026-05-27. Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC. https://investors.nuvalent.com/2026-05-27-Nuvalent-Announces-Key-Program-and-Business-Updates,-Strengthening-Foundation-for-Global-Leadership-in-ROS1-and-ALK-positive-NSCLC
  6. ClinicalTrials.gov · 2026-11-18. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1). https://clinicaltrials.gov/study/NCT05384626
  7. ClinicalTrials.gov · 2026-11-18. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC. https://clinicaltrials.gov/study/NCT06765109
  8. LUNGevity Foundation. About ALK-positive Lung Cancer | Navigating ALK. https://alk.lungevity.org/alk/about-alk-positive-lung-cancer
  9. U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (alectinib hydrochloride) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
  10. U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (lorlatinib) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
  11. U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (brigatinib) tablet, film coated; kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
  12. U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (crizotinib) capsule; capsule, coated pellets. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
  13. U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (ceritinib) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e
  14. U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ensartinib) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Nelkarmi by email

We'll email you when Nelkarmi's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site